Bladder Cancer Therapeutics and Diagnostics Market to grow with a CAGR of 7.50%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Bladder Cancer Therapeutics and Diagnostics Market.
According
to TechSci Research report, “Global Bladder Cancer Therapeutics and
Diagnostics Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global
Bladder Cancer Therapeutics and Diagnostics Market has valued at USD 450 million
in 2022 and is anticipated to witness an impressive growth in the forecast
period with a CAGR of 3.90% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
Technological
integration in bladder cancer therapeutics and diagnostics involves the
incorporation of advanced technologies into the diagnosis, treatment, and
management of bladder cancer. This integration aims to improve accuracy,
efficiency, and patient outcomes. Enhanced cystoscopy techniques using
fluorescence can improve the visualization of bladder tumors. This integration
enhances the accuracy of tumor detection. The integration of biomarker
detection technologies allows for non-invasive testing of urine samples to
identify cancer-specific biomarkers associated with bladder cancer. Telemedicine
platforms facilitate virtual consultations, remote monitoring, and data
sharing, allowing patients to access bladder cancer care more conveniently,
especially for follow-up visits and consultations. AI algorithms are used to
analyze medical imaging data, such as CT scans and MRI images, to detect and
classify bladder tumors accurately.
Bladder
cancer, which often affects older people, is described as the unchecked
proliferation of abnormal cells in the urinary bladder. Early identification is
crucial since the spread of malignant cells into the muscle wall of the bladder
is harmful to one's health. In addition to tobacco use and exposure to some
harmful chemicals and gases, surgery, biological therapy, and chemotherapy are
the most often used treatments for bladder cancer. While it is less frequent in
women, bladder cancer is the fourth most common type of cancer in men.
In
July 2022, The FDA has accepted ImmunityBio, Inc.'s Biologics License
Application (BLA) for review in relation to its antibody cytokine fusion
protein as a treatment for patients with non-muscle-invasive bladder cancer
carcinoma in situ (CIS) that is unresponsive to BCG and may or may not have Ta
or T1 illness. Several investigations of the experimental medicine, including
the ongoing QUILT 3.032 study, produced encouraging results, which encouraged
ImmunityBio, a top clinical-stage immunotherapy business, to file the BLA. This
N-803 and BCG combination is ImmunityBio's first BLA to advance to this FDA
review acceptance level. This represents a significant step towards realizing
ImmunityBio's objective of treating cancer patients differently by stimulating
their innate immune systems rather than using high-dose chemotherapy. The
unique method of action of N-803 promotes the growth of NK and T cells, which
are components of the innate and adaptive immune systems. By doing this, N-803
enhances the immune response brought on by BCG in the case of bladder cancer or
a checkpoint inhibitor in other circumstances.
Late-stage diagnosis is indeed a significant challenge
in the Global Bladder Cancer Therapeutics and Diagnostics Market. Bladder
cancer, like many other cancers, is more treatable when detected at an early
stage.
Late-stage bladder cancer often requires more
aggressive treatments, such as radical cystectomy (removal of the bladder) or
extensive chemotherapy and radiation therapy. These treatments can be more
invasive and have a higher risk of complications. Late-stage
diagnosis means that the cancer has had more time to grow and potentially
spread to nearby tissues or distant organs. This increases the complexity of
treatment and reduces the likelihood of a complete cure. Late-stage
bladder cancer is associated with a less favourable prognosis. The chances of
long-term survival and disease-free outcomes decrease as the cancer advances.
Browse
over XX market data Figures and spread through 110 Pages and an in-depth TOC
on "Bladder Cancer Therapeutics and Diagnostics Market.”
Global Bladder Cancer Therapeutics and Diagnostics Market
segmentation is based on therapeutics, diagnostics, cancer type, and Region.
Based on cancer type, Global Bladder Cancer
Therapeutics and Diagnostics Market is segmented into Transitional Cell Bladder
Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. Squamous cell bladder cancer, also
known as squamous cell carcinoma of the bladder, is a relatively rare type of
bladder cancer that originates in the squamous cells lining the bladder's inner
surface. Most bladder cancers, about 90%, are urothelial carcinomas
(transitional cell carcinomas) that begin in the urothelial cells that line the
bladder. Squamous cell bladder cancer, on the other hand, starts in the
squamous epithelial cells, which are flat, thin cells found in tissues lining
various parts of the body, including the urinary tract. The symptoms of
squamous cell bladder cancer are like those of other types of bladder cancer
and may include hematuria (blood in the urine), frequent urination, painful
urination, and lower abdominal pain.
Based on Region, North America dominated the Global Bladder Cancer Therapeutics and Diagnostics
Market. North America has access to significant financial resources,
including venture capital and private equity funding. This financial support
facilitates the development and commercialization of novel bladder cancer
treatments and diagnostics. The United States has a well-established regulatory
authority, the Food and Drug Administration (FDA), known for its rigorous but
predictable approval process. This regulatory clarity can incentivize companies
to invest in bladder cancer product development. North America is home to some
of the world's leading academic and medical institutions, which collaborate
with industry partners to advance bladder cancer research and develop
cutting-edge diagnostics and therapeutics. There are active patient advocacy
groups and organizations in North America dedicated to bladder cancer
awareness, research funding, and support. These groups contribute to increased
awareness and early detection efforts.
Asia-pacific region to fastest growth in the Global Bladder
Cancer Therapeutics and Diagnostics Market. The APAC region is home to a
significant and rapidly aging population. As people age, the risk of developing
bladder cancer increases. The rising elderly population is contributing to an
increase in bladder cancer incidence, driving the demand for therapeutics and
diagnostics. Urbanization and changing lifestyles in many APAC countries have
led to an increase in risk factors associated with bladder cancer, such as
tobacco smoking, exposure to environmental pollutants, and dietary habits.
These lifestyle changes have contributed to the growing incidence of bladder
cancer in the region. Many APAC countries are witnessing significant growth in
healthcare spending, both by governments and individuals. As healthcare
infrastructure improves and access to healthcare services expands, more
patients are likely to seek diagnosis and treatment for bladder cancer.
Some
of the major companies operating in the Global
Bladder Cancer Therapeutics and Diagnostics Market include:
- Ameritech
Diagnostic Reagent (Jiaxing)Co., Ltd
- Bristol-Myers
Squibb Company
- Eli
Lilly and Company
- F.
Hoffmann-La Roche Ltd
- GlaxoSmithKline
PLC
- Novartis
International AG
- Pfizer
Inc.
- Abbott
Inc.
- Endo
Pharmaceuticals Inc.
- Johnson
& Johnson (Janssen Pharmaceutical)
- Merck
& Co. Inc
- Astellas
Pharma Inc.
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand of bladder cancer therapies.
The growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Bladder
Cancer Therapeutics and Diagnostics Market in the forecast period," said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
Global management consulting firm.
Bladder
Cancer Therapeutics and Diagnostics Market – Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented by Therapeutics
(Chemotherapy, Immunotherapy, Other Therapeutics), by Diagnostics (Cystoscopy,
Bladder Ultrasound, Urinalysis, Other Diagnostics)), by Cancer Type
(Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer
Types), By Region, and Competition evaluated
the future growth potential of Global Bladder Cancer Therapeutics and
Diagnostics Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Bladder Cancer
Therapeutics and Diagnostics Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com